CompletedPhase 2NCT03954327

Combination Antiretroviral Therapy (cART) for PBC

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Alberta
Principal Investigator: Andrew Mason, MD
University of Alberta
Intervention: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)(drug)
Enrollment: 37 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2024

Study locations (6)

University of Alberta, Edmonton, Alberta, Canada
St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Vancouver General Hospital, University of Brittish Columbia, Vancouver, British Columbia, Canada
University of Toronto, Toronto, Ontario, Canada
University of Montreal, Montreal, Quebec, Canada
Royal University Hospital, Saskatoon, Saskatchewan, Canada

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03954327 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials